

## Product datasheet for **TL308331V**

### Tyrosyl tRNA synthetase (YARS) Human shRNA Lentiviral Particle (Locus ID 8565)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Tyrosyl tRNA synthetase (YARS) Human shRNA Lentiviral Particle (Locus ID 8565)
Locus ID:	8565
Synonyms:	CMTDIC; TYRRS; YARS; YRS; YTS
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	YARS - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_003680</a> , <a href="#">NM_003680.1</a> , <a href="#">NM_003680.2</a> , <a href="#">NM_003680.3</a> , <a href="#">BC016689</a> , <a href="#">BC001933</a> , <a href="#">BC004151</a> , <a href="#">BC035242</a>
UniProt ID:	<a href="#">P54577</a>
Summary:	Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Tyrosyl-tRNA synthetase belongs to the class I tRNA synthetase family. Cytokine activities have also been observed for the human tyrosyl-tRNA synthetase, after it is split into two parts, an N-terminal fragment that harbors the catalytic site and a C-terminal fragment found only in the mammalian enzyme. The N-terminal fragment is an interleukin-8-like cytokine, whereas the released C-terminal fragment is an EMAP II-like cytokine. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).